<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="919">
  <stage>Registered</stage>
  <submitdate>30/11/2005</submitdate>
  <approvaldate>7/12/2005</approvaldate>
  <actrnumber>ACTRN12605000777695</actrnumber>
  <trial_identification>
    <studytitle>A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145mg fenofibrate and simvastatin with 40mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone</studytitle>
    <scientifictitle>A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145mg fenofibrate and simvastatin with 40mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Patients with mixed dyslipidemia with CHD or CHD risk equivalent or with multiple risk factor and a 10 year risk above or equal to 10% and with TG above 1.71mmol/l and LDL &gt;2.58 or &gt;3.36mmol/l according to risk after 6 weeks of treatment with 40mg simvastatin.</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Coprescription fenofibrate 145mg and simvastatin 40mg</interventions>
    <comparator>Simvastatin 40mg</comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>TG</outcome>
      <timepoint>At 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>LDL-C</outcome>
      <timepoint>At 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Non-HDL-C, Total Cholesterol, ApoA1, AopB, hsCRP.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fibrinogen</outcome>
      <timepoint>At 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with mixed dyslipidemia with CHD or CHD risk equivalent or with multiple risk factor and a 10 year risk above or equal to 10% and with TG above 1.71mmol/l and LDL &gt;2.58 or &gt;3.36mmol/l according to risk after 6 weeks of treatment with 40mg simvastatin.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Diabetes, CK&gt;2 times ULN, creatinine clearance &gt; 80ml/min, LFTs &gt;2 times ULN.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Treatment will be assigned at the randomisation visit (V2) to patients compliant with the inclusion/exclusion/randomisation criteria by a centralised randomisation centre.</concealment>
    <sequence>Random allocation by computer software using four block-balanced randomisation lists (one for male patients with the highest level of CVD risk, one for male patients with the lowest level of risk, one for female patients with the highest level of risk and one for female patients with the lowest level of risk).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>15/12/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Fournier Laboratories Ireland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Ireland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Fournier Laboratories Ireland</fundingname>
      <fundingaddress />
      <fundingcountry>Ireland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Francis Roy</name>
      <address>Laboratoires Fournier SA
50 rue de Dijon
21121 Daix</address>
      <phone>+33 3 80447582</phone>
      <fax />
      <email>f.roy@fr.fournierpharma.com</email>
      <country>France</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Martine Guy</name>
      <address>Laboratoires Fournier SA
50 rue de Dijon
21121 Daix</address>
      <phone>+33 3 80447583</phone>
      <fax />
      <email>m.guy@fr.fournierpharma.com</email>
      <country>France</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>